Literature DB >> 17201130

Evaluation of cancer chemopreventive agents using clones derived from a human prostate cancer cell line.

Jeffrey H Ware1, Zhaozong Zhou, Levy Kopelovich, Ann R Kennedy.   

Abstract

BACKGROUND: The successful use of clonal selection through fluctuation analysis of human cancer cells as a means for studying tumor progression has been previously reported.
MATERIALS AND METHODS: Three clones derived from a parental population of human prostate cancer (LNCaP) cells were selected based on proliferation, hormone sensitivity and anchorage-independent growth. The effects of five potential cancer preventive agents were evaluated using cell proliferation, anchorage-independent growth and apoptosis as end-points.
RESULTS: Clone 21 cells, which represent a presumptive normal phenotype, were generally more sensitive than Clone 17 and Clone 6 cells, which represent a more malignant phenotype, to fluasterone, 7beta-HF, L-selenomethionine and troglitazone in assays for proliferation and/or apoptosis.
CONCLUSION: The results confirm the efficacy of the above agents as cancer chemopreventive agents and support our contention that clonal selection of established human cancer cells provides a model to study the efficacy of chemopreventive agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201130

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

2.  Rapid access to preventive intervention development program in the Division of Cancer Prevention of the U.S. National Cancer Institute: an overview.

Authors:  Izet M Kapetanovic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-24       Impact factor: 4.254

3.  Effects of selenomethionine on the gene expression profile of cloned human prostate cancer cells representing a phenotypic continuum of cancer progression.

Authors:  Jelena Stewart; Jeffrey Ware; Cecilie Boysen; Sandeep Gulati; Zhaozong Zhou; Simon Rosenfeld; Levy Kopelovich; Ann R Kennedy
Journal:  Nutr Cancer       Date:  2008       Impact factor: 2.900

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.